SAS Output

25-APR-2019 6:10

GU ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1500-pRCC,Adv, Sunitinib vs MET inhib 1 Y 1 Sunitinib 148 33 13 6 2 1 0 07/25/2016 213 87
        2 Cabozantinib   32 14 5 4 2 0      
        3 Crizotinib   28 7 0 0 0 0      
        4 Savolitinib   30 10 1 0 0 0      
            123 44 12 6 3 0      
 
  S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 969 106 74 47 32 15 2 02/24/2017 173 70
        2 Tokyo-172 BCG   106 75 47 32 16 4      
        3 Prime + Tokyo-172 BCG   104 75 48 31 16 3      
            316 224 142 95 47 9      
 
  S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab 1 Y 1 Atezolizumab 162 144 103 56 28 12 2 03/13/2017 197 91
            144 103 56 28 12 2      
 
  S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 1273 55 55 47 26 12 2 09/24/2018 222 90
            55 55 47 26 12 2      
 
    2 Y 1 Standard Systemic Therapy Only 1273 11 11 10 7 3 0 09/24/2018    
        2 SST + Surgery/RT   11 11 10 6 3 1      
            22 22 20 13 6 1      
 
Yes A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 1 E Total Registrations   5 2 1 1 1 0 11/23/2016 63 40
            5 2 1 1 1 0      
 
  EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) 0 E Total Registrations   47 33 25 16 7 2 09/29/2017 330 146
            47 33 25 16 7 2      
 
    1 E Total Registrations   38 27 21 14 7 0 09/29/2017    
            38 27 21 14 7 0      
 
  EA8171-PROS, newly diagnosed, mpMRI for pre-op stagi 1 E Total Registrations   3 3 3 3 1 0 02/11/2019 80 29
            3 3 3 3 1 0      
 
  NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel 1 E Total Registrations   3 2 2 1 0 0 08/24/2017 220 104
            3 2 2 1 0 0      
 
    2 E Total Registrations   3 2 2 1 0 0 08/24/2017    
            3 2 2 1 0 0      
 
  NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT 1 E Total Registrations   1 1 1 1 0 0 03/19/2019 7 3
            1 1 1 1 0 0      
 
No A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 0 E Total Registrations   36 36 27 12 4 0 05/03/2018 241 125
            36 36 27 12 4 0      
 
    1 E Total Registrations   33 33 24 12 6 1 05/03/2018    
            33 33 24 12 6 1      
 
  A031701-Bladder, ddGC for MIBC with DDR Tumor Alt 1 E Total Registrations   1 1 1 0 0 0 12/17/2018 16 4
            1 1 1 0 0 0      
 
    2 E Total Registrations   1 1 1 1 0 0 12/17/2018    
            1 1 1 1 0 0      
 
  EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 1 E Total Registrations   5 5 3 1 1 0 08/08/2018 102 27
            5 5 3 1 1 0      
 
  NRGGU006-PROS, post-RP PSA, SRT +/- ADT w/Apalutamide 1 E Total Registrations   2 2 2 2 1 0 03/22/2019    
            2 2 2 2 1 0      
 
    2 E Total Registrations   1 1 1 1 1 1 03/22/2019    
            1 1 1 1 1 1      
 
  R0924-Pros, NADT+WPRT vs. NADT+P&SV RT 1 E Total Registrations   92 20 3 1 0 0 11/25/2013 260 115
            92 20 3 1 0 0      
 

25-APR-2019 6:10

GU Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1806 Blad, MIBC, ChemoRT +/- Atezolizumab 1 Registration 19-Apr-19
  2 Randomization 19-Apr-19